GeoVax Labs, Inc., a clinical-stage biotechnology company, is set to present significant findings from its Phase II randomized clinical trial at the European Hematology Association (EHA) 2025 Hybrid Congress. The study highlights the enhanced cellular immune response of GEO-CM04S1, a next-generation COVID-19 vaccine, in patients with Chronic Lymphocytic Leukemia (CLL), a group known for their compromised immune responses to vaccines.
The presentation, led by Dr. Alexey V. Danilov, will detail how GEO-CM04S1, developed using GeoVax's MVA multi-antigen platform, outperforms authorized mRNA-based COVID-19 vaccines in eliciting immune responses in CLL patients. This development is crucial as it addresses the unmet need for effective vaccination strategies in immunocompromised individuals, particularly those with hematologic malignancies who are at higher risk of severe COVID-19 outcomes.
GEO-CM04S1's design, which includes both spike and nucleocapsid antigens of SARS-CoV-2, aims to offer broader and more durable protection. The upcoming presentation at EHA 2025 underscores the vaccine's potential to fill a critical gap in current vaccination efforts, especially for vulnerable populations. Dr. Kelly T. McKee, Jr., GeoVax's Chief Medical Officer, emphasized the importance of these findings in meeting the real-world needs of patients with hematologic malignancies.
